281 Results

FDA approves Trazimera biosimilar to Herceptin to treat breast and gastric cancers

 Added 6 days ago

The FDA has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor-2...

FDA grants accelerated approval for Tecentriq + Abraxane in metastatic triple-negative breast cancer

 Added 15 days ago

Genentech/Roche announced the FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension...

CHMP positive for Lynparza to treat patients with germline BRCA1/2-mutations who have HER2 negative locally advanced or metastatic breast cancer

 Added 22 days ago

AstraZeneca and Merck Inc., announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

FDA approves Herceptin Hylecta for subcutaneous injection for the treatment of certain people with HER2-positive early breast cancer

 Added 23 days ago

Genentech, a member of the Roche Group announced the FDA has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under...

European Commission approves Zirabev (bevacizumab biosimilar)to treat the same indications as the originator product. Avastin. - Pfizer

 Added 1 month ago

Pfizer Inc. announced the European Commission (EC) has approved Zirabev for the treatment of metastatic carcinoma of the colon or...

Genentech completes sBLA for Kadcyla for adjuvant treatment of HER2-positive early breast cancer (EBC) with residual disease.

 Added 1 month ago

Genentech, a member of the Roche Group announced completing the submission of a supplemental Biologics License Application to the FDA...

Phase III SOFIA study of MGAH 22 meets primary endpoint in breast cancer.- MacroGenics

 Added 1 month ago

MacroGenics announced positive results from SOPHIA, the Company’s Phase III clinical study of MGAH 22 (margetuximab) in HER2-positive metastatic breast...

Genentech/Roche file sBLA with FDA for Kadcycla as adjuvant treatment in HER2+ breast cancer

 Added 1 month ago

Genentech/Roche announced completing the submission of a supplemental Biologics License Application to the FDA for Kadcyla (ado-trastuzumab emtansine) for adjuvant...

FDA approves Ontruzant biosimilar for all indications of Herceptin.- Samsung Bioepis + Merck Inc.

 Added 2 months ago

Samsung Bioepis Co., Ltd. announced that the FDA has approved Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible...

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

 Added 2 months ago

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

Load more